Compare HMH & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMH | NNNN |
|---|---|---|
| Founded | 2021 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Oil and Gas Field Machinery | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 270.4M |
| IPO Year | 2024 | 2023 |
| Metric | HMH | NNNN |
|---|---|---|
| Price | $18.81 | $4.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $28.71 | N/A |
| AVG Volume (30 Days) | ★ 195.9K | 180.8K |
| Earning Date | 11-23-2026 | 10-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.82 | N/A |
| P/E Ratio | ★ $14.22 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.87 | $4.66 |
| 52 Week High | $22.34 | $44.73 |
| Indicator | HMH | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 27.52 |
| Support Level | $18.30 | N/A |
| Resistance Level | $20.16 | $6.95 |
| Average True Range (ATR) | 0.84 | 0.52 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 68.04 | 3.96 |
HMH Holding Inc is a provider of offshore and onshore drilling equipment and services in the United States and Norway. Its services include sales of projects and products including drilling equipment packages for newbuild or a reactivated drilling rig, and individual or grouped components of drilling and pressure control equipment. The company also offers aftermarket services including services and replacement parts on installed equipment and integrated digital solutions. The company sells equipment and services to drilling contractors; operators, including both oil and gas E&P companies and mining companies onshore and offshore; and manufacturers, consisting of shipyards.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).